36 patents
Page 2 of 2
Utility
Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
18 Mar 21
This invention is in the area of improved compounds and methods for transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC), from the damage associated with ionizing radiation (IR) exposure using selective radioprotectants.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Filed: 23 Nov 20
Utility
Pyrimidine-based Antiproliferative Agents
18 Feb 21
This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
Jay Copeland Strum, David Jung
Filed: 3 Nov 20
Utility
Treatment of Cancers Having Driving Oncogenic Mutations
4 Feb 21
Methods and compositions are described to treat a cancer having a specific oncogenic driving mutation by administering a CDK4/6 inhibitor in combination with an additional kinase inhibitor, wherein the specific combination provides advantageous or synergistic inhibitory activity, delays acquired resistance to the additional kinase inhibitor, and/or extends the efficacy of the kinase inhibitor.
Jay Copeland Strum, Daniel M. Freed, Jessica A. Sorrentino, John E. Bisi, Andrew Beelen, Patrick Joseph Roberts
Filed: 9 Oct 20
Utility
G1T38 Superior Dosage Regimes
30 Dec 20
A G1T38 human oral dosage regime that provides a (mean AUC(0-24),ss (h*ng/mL))/(dose (mg)) ratio of less than 5 and/or a (mean AUC(0-24),ss (h*ng/mL))/(Absolute Neutrophil Count (cells/mm3)) ratio on day 22 of dosing of not greater than 1.25.
Andrew Beelen, Jay Copeland Strum
Filed: 7 Jul 20
Utility
Transient Protection of Normal Cells During Chemotherapy
4 Nov 20
This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Filed: 27 May 20
Utility
Highly Active Anti-neoplastic and Anti-proliferative Agents
4 Nov 20
This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Filed: 9 Jul 20
Utility
Heterocyclic Compounds for the Treatment of Abnormal Cellular Proliferation
21 Oct 20
This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
Jay Copeland Strum, David Jung
Filed: 30 Jun 20
Utility
Antiproliferative Pyrimidine-based Compounds
9 Sep 20
This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
Jay Copeland Strum, Ricky D. Gaston, Robert C. Gadwood
Filed: 17 May 20
Utility
CDK Inhibitors
2 Sep 20
Compounds of Formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
Francis X. Tavares, Jay Copeland Strum
Filed: 12 May 20
Utility
Pyrimidine-based Compounds for the Treatment of Cancer
29 Jul 20
This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
Jay Copeland Strum
Filed: 12 Apr 20
Utility
Benzothiophene Estrogen Receptor Modulators
8 Jul 20
This invention is a benzothiophene estrogen receptor modulator or its pharmaceutically acceptable salt or a pharmaceutically acceptable composition thereof to treat an estrogen-related medical disorder.
Jay Copeland Strum
Filed: 18 Mar 20
Utility
Morphic Forms of G1T38 and Methods of Manufacture Thereof
22 Apr 20
This invention provides an unexpectedly stable, highly crystalline form of the di-HCl salt of 2′-((5-(4-isopropylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one for advantageous therapeutic pharmaceutical efficacy and dosage form stability.
Alexander Smith, Hannah S. White, Patrica Andres, Xufeng Sun, Lei Zhu, Petinka I. Vlahova
Filed: 18 Dec 19
Utility
Treatment of Rb-negative Tumors Using Topoisomerase Inhibitors In Combination with Cyclin Dependent Kinase 4/6 Inhibitors
22 Jan 20
This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4/6 (CDK4/6) inhibitors.
Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino
Filed: 15 Sep 19
Utility
Treatment of Egfr-driven Cancer with Fewer Side Effects
11 Dec 19
The present invention provides methods for treating a EGFR-mutant cancer in a patient by administering a selective CDK4/6 inhibitor described herein in combination or alternation with an EGFR-TKI to delay or reverse acquired resistance to previously administered EGFR-TKIs.
Jessica A. Sorrentino, Jay Copeland Strum, John E. Bisi, Andrew Beelen
Filed: 20 Aug 19
Utility
Combination Therapy for Treatment of Cancer
23 Oct 19
Compositions, combinations and methods comprising a CDK4/6 inhibitor of Formula D with a selective estrogen receptor downregulator of Formula A, B or C that are advantageous for the treatment of abnormal cellular proliferation, including a cancer or a tumor.
JAY C. STRUM, Gregory R. Thatcher, Rui Xiong, Jiong Zhao, Debra A. Tonetti
Filed: 1 Jul 19
Utility
Preservation of Immune Response During Chemotherapy Regimens
23 Oct 19
The addition of a selective, fast-acting, short half-life CDK 4/6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer.
Jessica A. Sorrentino, Ann Y. Lai, Jay C. Strum, Patrick Joseph Roberts
Filed: 4 Jun 19